Cytek Biosciences, Inc. (CTKB)

Cytek Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-11.25	-6.02	-12.15	2.58	3.05	19.41
Depreciation & Amortization	10.91	10.49	9.23	5.66	1.24	0.6
Loss (Gain) From Sale of Assets	0.11	0.06	0.01	-	-	-
Asset Writedown & Restructuring Costs	-	-	-	-	0.28	-
Loss (Gain) From Sale of Investments	-5.5	-5.21	-6.66	-0.08	-	-
Loss (Gain) on Equity Investments	-	-	-	-	-0.04	-
Stock-Based Compensation	27.84	26.85	22.05	16.6	6.59	0.61
Provision & Write-off of Bad Debts	-0.19	-0.06	0.27	0.1	-	0.18
Other Operating Activities	-9.52	-8.43	3.05	2.84	2.15	1.89
Change in Accounts Receivable	-3.21	-5.43	-7.33	-19.74	-12.37	0.33
Change in Inventory	8.48	14.76	4.29	-17.65	-7.07	-5.7
Change in Accounts Payable	2.38	2.58	-1.78	1.86	-0.26	-0.06
Change in Unearned Revenue	4.54	3.74	6.52	9.41	10.01	2.38
Change in Other Net Operating Assets	-3.29	-7.93	-12.2	-13.8	1.03	-4.49
Operating Cash Flow	21.3	25.38	5.28	-12.23	4.63	15.16
Operating Cash Flow Growth	233.81%	380.57%	-	-	-69.45%	-
Capital Expenditures	-3.81	-3.53	-4.65	-9.75	-4.36	-1.55
Sale of Property, Plant & Equipment	0.32	0.29	-	-	-	-
Cash Acquisitions	-0.47	-0.47	-45.13	-	-16.63	-
Sale (Purchase) of Intangibles	-0.15	-0.2	-0.18	-0.12	-	-
Investment in Securities	-63.66	-79.06	-43.94	-46.04	-	-
Investing Cash Flow	-67.77	-82.97	-93.89	-55.91	-20.99	-1.55
Short-Term Debt Issued	-	4.18	-	-	-	4.08
Long-Term Debt Issued	-	-	-	2.98	-	-
Total Debt Issued	3.48	4.18	-	2.98	-	4.08
Short-Term Debt Repaid	-	-	-	-	-2.77	-1.31
Long-Term Debt Repaid	-	-0.56	-0.57	-0.05	-	-
Total Debt Repaid	-1.94	-0.56	-0.57	-0.05	-2.77	-1.31
Net Debt Issued (Repaid)	1.54	3.62	-0.57	2.93	-2.77	2.77
Issuance of Common Stock	2.25	2.72	3.32	2.79	216.33	0.17
Repurchase of Common Stock	-32.77	-22.17	-44.57	-0.21	-	-
Financing Cash Flow	-28.98	-15.82	-41.81	5.51	213.56	122.61
Foreign Exchange Rate Adjustments	1.61	4.53	-1.45	-2.49	1.3	-0.59
Net Cash Flow	-73.84	-68.89	-131.87	-65.12	198.5	135.63
Free Cash Flow	17.49	21.85	0.63	-21.98	0.27	13.61
Free Cash Flow Growth	947.31%	3352.45%	-	-	-98.05%	-
Free Cash Flow Margin	8.88%	10.90%	0.33%	-13.40%	0.21%	14.66%
Free Cash Flow Per Share	0.14	0.17	0.01	-0.16	0.00	0.42
Cash Income Tax Paid	3.83	3.83	5.31	10.39	2.86	2.07
Levered Free Cash Flow	30.18	36.25	-1.34	-23.76	-6.21	4.97
Unlevered Free Cash Flow	30.18	36.25	-0.04	-22.15	-5.12	5.18
Change in Net Working Capital	-12.49	-17.1	9.09	33.41	14.31	3.02

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q